MigVax

Vaccine for Viruses in Humans

Health Tech & Life Sciences
Active
Series A Qiryat Shemona, Israel Founded 2020
Last updated 2026-06-18
Total raised
$21.3M
Last: 2022-08
Stage
Series A
Founded
2020
Headcount
9
HQ
Qiryat Shemona, Israel
Sector
Health Tech & Life Sciences

About

MigVax was established as a special purpose vehicle by Migal, which granted MigVax an exclusive, worldwide license to make, use, and practice the vaccine technology for the development, manufacture, and commercialization of vaccines for viruses in humans, starting with COVID-19.

The COVID-19 vaccine project was initiated upon the interdisciplinary research team’s successful development of a vaccine against infectious bronchitis virus (IBV), an avian (poultry) coronavirus with high similarity to today’s human COVID-19 that uses the same infection mechanism. Given the similarity, and following the required genetic adjustments, the same vaccination concepts should apply.

MigVax’s sub-unit vaccine approach utilizes a chimeric protein that presents the viral proteins to the immune system via the oropharynx. This method, based on the IBV vaccine, generates three types of immunological response: mucosal immunity (IgA), blood-based immunity (IgG), and cell-mediated immunity.

Funding history · 4 rounds · $21.3M total

2022-08
$500K
2021-12
$500K

Q&A

What is MigVax's primary focus?
MigVax is focused on developing vaccines for viruses in humans, initially targeting COVID-19. Their approach is based on a successful vaccine against an avian coronavirus with similarities to human COVID-19.
When was MigVax founded?
MigVax was founded in March 2020.
How much funding has MigVax raised to date?
MigVax has raised a total of $21.3 million USD.
Which investors participated in MigVax's April 2020 funding round?
In April 2020, MigVax received funding from OurCrowd and Happiness Capital.
Did MigVax receive any grants?
Yes, in November 2021, MigVax received a grant of $4.3 million USD from The Coalition of Epidemic Preparedness Innovations (CEPI).
Who is the CEO of MigVax?
Ran Amir is the CEO of MigVax.
What is MigVax's current product stage?
MigVax's product is currently in the R&D stage.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Tags

immunologypharmaceuticalsdrug-developmentoral-drugsvaccines
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitemigvax.com/
LinkedInlinkedin.com/company/82100394

Identifiers & details

Founded2020-3
Employees (exact)9

Radar intelligence

Patents

EPO1

Web history (Wayback)

Domainmigvax.com

Certificate / subdomain footprint

Subdomains2